Memic Raises $96M for Surgical Robot

In the realm of medical technology, Memic emerges as a frontrunner with its robotic-assisted surgical platform, Hominis, which recently obtained marketing authorization from the U.S. Food and Drug Administration (FDA). Today, the company announces the closure of a $96 million Series D funding round, spearheaded by Peregrine Ventures and Ceros, alongside OurCrowd and Accelmed.

This substantial investment signals Memic's intent to propel the commercialization of its platform in the U.S. market and extend its marketing and sales endeavors globally. With previous funding totaling $31.8 million, including notable contributions from crowdsourcing platform OurCrowd, Memic is poised to revolutionize the landscape of robotic surgery.

Named Hominis, the platform has garnered FDA approval for use in specific surgical procedures, notably "single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy." Notably, Hominis operates under the supervision of surgeons, who control its robotic arms from a central console, ensuring precise and controlled maneuvers mimicking the surgeon's motions.

While currently authorized for a specific procedure, Memic envisions a broader spectrum of applications where its robotic system could offer significant benefits. Dvir Cohen, Memic's co-founder and CEO, emphasizes the platform's potential in advancing the burgeoning market of robotic surgery. The financing round positions Memic to accelerate its commercialization efforts, making Hominis accessible to surgeons and patients alike in the foreseeable future.

Although Memic's Hominis enters a market with existing computer-assisted surgical systems, its unique focus on benign transvaginal procedures sets it apart. While competitors like Asensus Surgical and ForSight explore different facets of robotic surgery, Memic pioneers a niche previously untapped. Investors bet on Hominis as a pioneering force, anticipating its expansion into diverse surgical domains in the coming years, marking a significant milestone in the evolution of robotic-assisted surgery.